Path ID: DB11595_MESH_D002295_1
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:C000594389 | Atezolizumab | Drug |
| UniProt:Q9NZQ7 | Programmed cell death 1 ligand 1 | Protein |
| GO:0042098 | T cell proliferation | BiologicalProcess |
| GO:0042110 | T cell activation | BiologicalProcess |
| GO:0002424 | T cell mediated immune response to tumor cell | BiologicalProcess |
| MESH:D002295 | Transitional cell carcinoma | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Atezolizumab | DECREASES ACTIVITY OF | Programmed Cell Death 1 Ligand 1 |
| Programmed Cell Death 1 Ligand 1 | NEGATIVELY REGULATES | T Cell Proliferation |
| Programmed Cell Death 1 Ligand 1 | NEGATIVELY REGULATES | T Cell Activation |
| T Cell Proliferation | POSITIVELY CORRELATED WITH | T Cell Mediated Immune Response To Tumor Cell |
| T Cell Activation | POSITIVELY CORRELATED WITH | T Cell Mediated Immune Response To Tumor Cell |
| T Cell Mediated Immune Response To Tumor Cell | NEGATIVELY CORRELATED WITH | Transitional Cell Carcinoma |
Comment: This medication is reserved for tumors that express PD-L1 or have high mutation burden.
Reference: